

# The Tetravalent Death Receptor 5 Agonist Ozekibart (INBRX-109) in Conventional Chondrosarcoma: Results From the Randomized, Registrational, Phase 2 ChonDRAGON Study



📅 Friday, November 14, 2025

Title: The Tetravalent Death Receptor 5 Agonist Ozekibart (INBRX-109) in Conventional Chondrosarcoma: Results From the Randomized, Registrational, Phase 2 ChonDRAGON Study

Lead Author: Robin Jones

Abstract: 31

Oral presentation Friday, November 14, 2025

 [CTOS 2025\\_ChonDRAGON Primary Data\\_Abstract\\_Nov25](#)  
(169 KB)

 [CTOS 2025\\_ChonDRAGON Oral Presentation\\_Nov25](#)  
(1012 KB)

<https://inhibrxbiosciences.investorroom.com/events-and-presentations?item=51>